therapeutic program (reMYND)

N/A

Report date: 2025/03/20 10:00:07
NME

Base Information

Drug Nametherapeutic program (reMYND)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsAmyotrophic Lateral SclerosisHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRemynd
China Registration ClassN/A

Develop Information

Active CompaniesRemynd
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A